Sigachi Industries has officially inaugurated its new state-of-the-art R&D Center in Hyderabad. This advanced facility is strategically designed to accelerate the development of critical Active Pharmaceutical Ingredients (APIs) and enhance in-house analytical capabilities. 

The Hyderabad R&D Center is equipped with advanced systems that integrate synthesis, analytics, and regulatory filing functions, ensuring seamless API development and global compliance. Sigachi has committed up to Rs 8.3 crore (approx. USD one million) in targeted investments to fuel its API pipeline and develop complex intermediates. The center will also support portfolio alignment with strategic therapeutic segments, enabling the company to focus its R&D resources effectively.

“This R&D Center reflects our vision of fostering a culture of scientific excellence and continuous improvement,” said a company spokesperson. “It will not only drive new product development but also reinforce our ability to deliver high-quality solutions to our global partners.”

Sigachi’s diverse portfolio includes APIs, intermediates, excipients, vitamin-mineral blends, and O&M services, manufactured across five facilities in Telangana, Gujarat, and Karnataka.